Under drug interactions, new clinical comments regarding concomitant systemic/inhaled/nasal/ophthalmic corticosteroids have been added.
The investigational fixed-dose treatment combines bictegravir (BIC) 50mg, a novel integrase strand transfer inhibitor (INSTI), with emtricitabine (FTC) 200mg and tenofovir alafenamide (TAF) 25mg, a dual-NRTI backbone.
Previous Phase 3 studies enrolling >4,500 women (ASPIRE and The Ring Study) have already demonstrated the vaginal ring to be safe and effective in protecting women aged 18-45 years against HIV.
The early-stage clinical trial studied "mosaic" vaccines created to induce immune responses against various HIV subtypes responsible for infections across the world.
A review of recent data showed that insemination with sperm from an HIV-negative donor is the safest option for a discordant couple where the woman does not have HIV but the man is HIV-positive.